ONCT(Delisted)
Oncternal·NASDAQ
--
--(--)
Signals Analysis
Bullish signal 1
Bearish signal 2
Revenue Beats Expectation
Shooting Star
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ONCT
Oncternal Therapeutics, Inc.
A biopharmaceutical company that developing therapeutics for cancers
12230 El Camino Real, Suite 300, San Diego, CA 92130
--
Oncternal Therapeutics, Inc., a Delaware corporation, was incorporated on September 24, 1997. The Company is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancer patients with critical unmet medical needs. Oncternal pursues drug development, targeting promising but untapped biological pathways related to cancer generation or progression, with a focus on prostate cancer and hematological malignancies.
Company Financials
EPS
ONCT has released its 2023 Q4 earnings. EPS was reported at -3.11, versus the expected -3.07, missing expectations. The chart below visualizes how ONCT has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ONCT has released its 2024 Q3 earnings report, with revenue of 494.00K, reflecting a YoY change of 175.98%, and net profit of -8.46M, showing a YoY change of 14.18%. The Sankey diagram below clearly presents ONCT's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
